Tenax Therapeutics, Inc. — News

Tenax Therapeutics NASDAQ: TENX reported that its Phase III LEVEL trial of oral levosimendan in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF, did not meet its primary endpoint, though the company said subgroup, biomarker and hemodynamic findings will inform its next steps in the program.

marketbeat.com - 2026-08-11 02:02:44

Tenax Therapeutics Inc. (NASDAQ:TENX) stock is trading lower on Monday after the company reported topline results from its Phase 3 LEVEL study evaluating oral levosimendan (TNX-103) in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

benzinga.com - 2026-08-10 12:02:44

Tenax Therapeutics, Inc. (TENX) Discusses Phase III LEVEL Trial Results for Oral Levosimendan in HFpEF Patients Transcript

seekingalpha.com - 2026-08-10 10:58:28

Tenax ​Therapeutics said on ‌Monday its experimental heart drug failed to meet the ​main goal of ​a late-stage study.

reuters.com - 2026-08-10 07:12:21

TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo

globenewswire.com - 2026-08-10 07:00:00

Tenax Therapeutics, Inc. (NASDAQ: TENX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the nine brokerages that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, seven have given a buy rating and one has assigned a strong buy rating to the

defenseworld.net - 2026-08-10 04:15:28

Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate progress.

globenewswire.com - 2026-07-31 07:00:00

The mean of analysts' price targets for Tenax Therapeutics (TENX) points to a 121.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

zacks.com - 2026-07-21 10:55:19

Tenax Therapeutics, Inc. is downgraded from Buy to Hold ahead of a major August 2026 phase 3 data readout for TNX-103 in PH-HFpEF. TNX-103 targets a large, unmet market with no approved therapies, but phase 3 success is uncertain despite promising phase 2 secondary endpoint results relating to 6MWD. The phase 3 LEVEL study is powered >90% to detect a 25-meter 6MWD change, but failure could cut TENX shares by 50% or more.

seekingalpha.com - 2026-07-06 14:11:37

CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it awarded inducement option awards on July 1, 2026 as material inducements to the employment of three non-executive individuals newly hired by the Company in various accounting, clinical operations, and CMC/product development roles.

globenewswire.com - 2026-07-02 16:05:00

Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that results from the Phase 3 LEVEL clinical trial will be presented in a Late-Breaking Clinical Science session at the European Society of Cardiology (ESC) Congress 2026, being held August 28-31 in Munich, Germany.

globenewswire.com - 2026-07-02 07:00:00

On track to report topline data from Phase 3 LEVEL study of TNX-103 in third quarter of 2026 Global Phase 3 LEVEL-2 clinical trial ongoing, enrollment completion anticipated by end of 2027 Strengthened leadership team with appointments of Thomas Staab as Chief Financial Officer and Timothy Healey, MBA, as Chief Commercial Officer CHAPEL HILL, N.C., May 12, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, reported today financial results for the quarter ended March 31, 2026 and provided an update on its recent corporate progress.

globenewswire.com - 2026-05-12 07:00:00